Comparison of carboplatin and doxorubicin-based chemotherapy protocols in 470 dogs after amputation for treatment of appendicular osteosarcoma

Journal of Veterinary Internal Medicine

Volumn 28, Issue 2, 2014, Pages 554-563

  Selmic, L E ^a   Burton, J H ^a   Thamm, D H ^a   Withrow, S J ^a   Lana, S E ^a  

^a Veterinary Dentistry and Oral Surgery   (United States)

Author keywords

Canine; Limb amputation; Oncology; Primary bone tumor

Indexed keywords

ANIMALIA; CANIS FAMILIARIS;

CARBOPLATIN; DOXORUBICIN;

AMPUTATION; ANIMAL; BONE NEOPLASMS; COMPARATIVE STUDY; DOG; DOG DISEASES; DRUG ADMINISTRATION; FEMALE; LIMB; MALE; OSTEOSARCOMA; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VETERINARY;

AMPUTATION; ANIMALS; BONE NEOPLASMS; CARBOPLATIN; DOG DISEASES; DOGS; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; EXTREMITIES; FEMALE; MALE; OSTEOSARCOMA; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84897646540     PISSN: 08916640     EISSN: 19391676     Source Type: Journal    
DOI: 10.1111/jvim.12313     Document Type: Article

References (36)

1. Straw RC, Withrow SJ, Powers BE. Management of canine appendicular osteosarcoma. Vet Clin North Am Small Animal Pract 1990;20:1141-1161.
2. Ehrhart NP, Ryan SD, Fan TM. Tumors of the skeletal system. Withrow SJ, Vail DM, Page RL, eds. Withrow & MacEwen's Small Animal Clinical Oncology, 5th ed. St. Louis, MO: Elsevier; 2013:463-503.
3. Berg J, Weinstein MJ, Schelling SH, et al. Treatment of dogs with osteosarcoma by administration of cisplatin after amputation or limb-sparing surgery: 22 cases (1987-1990). J Am Vet Med Assoc 1992;200:2005-2008.
4. Berg J, Gebhardt MC, Rand WM. Effect of timing of postoperative chemotherapy on survival of dogs with osteosarcoma. Cancer 1997;79:1343-1350.
5. Straw RC, Withrow SJ, Richter SL, et al. Amputation and cisplatin for treatment of canine osteosarcoma. J Vet Intern Med 1991;5:205-210.
6. Thompson JP, Fugent MJ. Evaluation of survival times after limb amputation, with and without subsequent administration of cisplatin, for treatment of appendicular osteosarcoma in dogs: 30 cases (1979-1990). J Am Vet Med Assoc 1992;200:531-533.
7. Mauldin GN, Matus RE, Withrow SJ, et al. Canine osteosarcoma. Treatment by amputation versus amputation and adjuvant chemotherapy using doxorubicin and cisplatin. J Vet Intern Med 1988;2:177-180.
8. Bergman PJ, MacEwen EG, Kurzman ID, et al. Amputation and carboplatin for treatment of dogs with osteosarcoma: 48 cases (1991 to 1993). J Vet Intern Med 1996;10:76-81.
9. Bacon NJ, Ehrhart NP, Dernell WS, et al. Use of alternating administration of carboplatin and doxorubicin in dogs with microscopic metastases after amputation for appendicular osteosarcoma: 50 cases (1999-2006). J Am Vet Med Assoc 2008;232:1504-1510.
10. Bailey D, Erb H, Williams L, et al. Carboplatin and doxorubicin combination chemotherapy for the treatment of appendicular osteosarcoma in the dog. J Vet Intern Med 2003;17:199-205.
11. Berg J, Weinstein MJ, Springfield DS, et al. Results of surgery and doxorubicin chemotherapy in dogs with osteosarcoma. J Am Vet Med Assoc 1995;206:1555-1560.
12. Chun R, Kurzman ID, Couto CG, et al. Cisplatin and doxorubicin combination chemotherapy for the treatment of canine osteosarcoma: A pilot study. J Vet Intern Med 2000;14:495-498.
13. Chun R, Garrett LD, Henry C, et al. Toxicity and efficacy of cisplatin and doxorubicin combination chemotherapy for the treatment of canine osteosarcoma. J Am Anim Hosp Assoc 2005;41:382-387.
14. Liptak JM, Dernell WS, Straw RC, et al. Proximal radial and distal humeral osteosarcoma in 12 dogs. J Am Anim Hosp Assoc 2004;40:461-467.
15. McMahon M, Mathie T, Stingle N, et al. Adjuvant carboplatin and gemcitabine combination chemotherapy postamputation in canine appendicular osteosarcoma. J Vet Intern Med 2011;25:511-517.
16. Moore AS, Dernell WS, Ogilvie GK, et al. Doxorubicin and BAY 12-9566 for the treatment of osteosarcoma in dogs: A randomized, double-blind, placebo-controlled study. J Vet Intern Med 2007;21:783-790.
17. Shapiro W, Fossum TW, Kitchell BE, et al. Use of cisplatin for treatment of appendicular osteosarcoma in dogs. J Am Vet Med Assoc 1988;192:507-511.
18. Kraegel SA, Madewell BR, Simonson E, et al. Osteogenic sarcoma and cisplatin chemotherapy in dogs: 16 cases (1986-1989). J Am Vet Med Assoc 1991;199:1057-1059.
19. Phillips B, Powers BE, Dernell WS, et al. Use of single-agent carboplatin as adjuvant or neoadjuvant therapy in conjunction with amputation for appendicular osteosarcoma in dogs. J Am Anim Hosp Assoc 2009;45:33-38.
20. Saam DE, Liptak JM, Stalker MJ, et al. Predictors of outcome in dogs treated with adjuvant carboplatin for appendicular osteosarcoma: 65 cases (1996-2006). J Am Vet Med Assoc 2011;238:195-206.
21. Longo DL, Duffey PL, DeVita VT, Jr., et al. The calculation of actual or received dose intensity: A comparison of published methods. J Clinical Oncol 1991;9:2042-2051.
22. Bacci G, Ferrari S, Longhi A, et al. Relationship between dose-intensity of treatment and outcome for patients with osteosarcoma of the extremity treated with neoadjuvant chemotherapy. Oncol Rep 2001;8:883-888.
23. Delepine N, Delepine G, Bacci G, et al. Influence of methotrexate dose intensity on outcome of patients with high grade osteogenic osteosarcoma. Analysis of the literature. Cancer 1996;78:2127-2135.
24. Eselgrim M, Grunert H, Kuhne T, et al. Dose intensity of chemotherapy for osteosarcoma and outcome in the Cooperative Osteosarcoma Study Group (COSS) trials. Pediatr Blood Cancer 2006;47:42-50.
25. Kawai A, Sugihara S, Kunisada T, et al. The importance of doxorubicin and methotrexate dose intensity in the chemotherapy of osteosarcoma. Arch Orthop Trauma Surg 1996;115:68-70.
26. Lewis IJ, Weeden S, Machin D, et al. Received dose and dose-intensity of chemotherapy and outcome in nonmetastatic extremity osteosarcoma. European Osteosarcoma Intergroup. J Clinical Oncol 2000;18:4028-4037.
27. Boerman I, Selvarajah GT, Nielen M, et al. Prognostic factors in canine appendicular osteosarcoma - A meta-analysis. BMC Vet Res 2012;8:56.
28. Sottnik JL, Rao S, Lafferty MH, et al. Association of blood monocyte and lymphocyte count and disease-free interval in dogs with osteosarcoma. J Vet Intern Med 2010;24:1439-1444.
29. Veterinary cooperative oncology group - Common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.1. Vet Comp Oncol 2011:1-30. doi:10.1111/j.1476-5829.2011.00283.x.
30. Frei E, 3rd, Elias A, Wheeler C, et al. The relationship between high-dose treatment and combination chemotherapy: The concept of summation dose intensity. Clin Cancer Res 1998;4:2027-2037.
31. Lachin JM, Foulkes MA. Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification. Biometrics 1986;42:507-519.
32. Lachin JM. Sample size and power for a logrank test and Cox proportional hazards model with multiple groups and strata, or a quantitative covariate with multiple strata. Stat Med 2013; doi:10.1002/sim.5839.
33. Lascelles BD, Dernell WS, Correa MT, et al. Improved survival associated with postoperative wound infection in dogs treated with limb-salvage surgery for osteosarcoma. Ann Surg Oncol 2005;12:1073-1083.
34. London C, Mathie T, Stingle N, et al. Preliminary evidence for biologic activity of toceranib phosphate (Palladia® in solid tumours. Vet Comp Oncol 2012;10:194-205.
35. Hagleitner MM, de BE, Te Loo DM. Survival trends and long-term toxicity in pediatric patients with osteosarcoma. Sarcoma 2012;2012; Article ID 636405, 5 pages.
36. Choeyprasert W, Natesirinilkul R, Charoenkwan P, et al. Carboplatin and doxorubicin in treatment of pediatric osteosarcoma: A 9-year single institute experience in the northern region of Thailand. Asian Pac J Cancer Prev 2013;14:1101-1106.